Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries.
(2009) In European Journal of Public Health 19(6). p.650-654- Abstract
- BACKGROUND: The aim of this study was to evaluate and compare the cost-effectiveness of varenicline with nicotine replacement therapy (NRT) for smoking cessation in four European countries (Belgium, France, Sweden and the UK). METHODS: Markov simulations, using the Benefits of Smoking Cessation on Outcomes (BENESCO) model, were performed. We simulated the incidence of four smoking-related morbidities: lung cancer, chronic obstructive pulmonary disease, coronary heart disease and stroke. The model computes quality-adjusted life-years gained and incremental cost-effectiveness ratios. Incremental cost-utility ratios were calculated, adopting a lifetime perspective. Efficacy data were obtained from a randomized open-label trial: Week 52... (More)
- BACKGROUND: The aim of this study was to evaluate and compare the cost-effectiveness of varenicline with nicotine replacement therapy (NRT) for smoking cessation in four European countries (Belgium, France, Sweden and the UK). METHODS: Markov simulations, using the Benefits of Smoking Cessation on Outcomes (BENESCO) model, were performed. We simulated the incidence of four smoking-related morbidities: lung cancer, chronic obstructive pulmonary disease, coronary heart disease and stroke. The model computes quality-adjusted life-years gained and incremental cost-effectiveness ratios. Incremental cost-utility ratios were calculated, adopting a lifetime perspective. Efficacy data were obtained from a randomized open-label trial: Week 52 continuous abstinence rates were 26.1% for varenicline and 20.3% for NRT. RESULTS: The analyses imply that for countries analysed, smoking cessation using varenicline versus NRT was associated with reduced smoking-related morbidity and mortality. The number of morbidities avoided, per 1000 smokers attempting to quit, ranged from 9.7 in Belgium to 6.5 in the UK. The number of quality-adjusted life-years gained, per 1000 smokers, was 23 (Belgium); 19.5 (France); 29.9 (Sweden); and 23.7 (UK). In all base-case simulations (except France), varenicline dominated (more effective and cost saving) NRT regarding costs per quality-adjusted life-year gained; for France the incremental cost-effectiveness ratio was 2803. CONCLUSION: This cost-effectiveness analysis demonstrated that since varenicline treatment was more effective, the result was increased healthcare cost savings in Belgium, Sweden and the UK. Our results suggest that funding varenicline as a smoking cessation aid is justifiable from a healthcare resource allocation perspective. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1434591
- author
- Bolin, Kristian LU ; Wilson, Koo ; Benhaddi, Hicham ; Nigris, Enrico de ; Marbaix, Sophie ; Mork, Ann-Christin and Aubin, Henri-Jean
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- nicotine replacement therapy, cost-effectiveness, smoking cessation, varenicline
- in
- European Journal of Public Health
- volume
- 19
- issue
- 6
- pages
- 650 - 654
- publisher
- Oxford University Press
- external identifiers
-
- wos:000272179400022
- pmid:19491286
- scopus:71449103289
- pmid:19491286
- ISSN
- 1101-1262
- DOI
- 10.1093/eurpub/ckp075
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Division of Health Economics and Forensic Medicine (Closed 2012) (013040050)
- id
- 16b2f74b-1db3-4008-a9bc-584e7c011d20 (old id 1434591)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19491286?dopt=Abstract
- date added to LUP
- 2016-04-01 12:16:40
- date last changed
- 2022-02-18 20:22:28
@article{16b2f74b-1db3-4008-a9bc-584e7c011d20,
abstract = {{BACKGROUND: The aim of this study was to evaluate and compare the cost-effectiveness of varenicline with nicotine replacement therapy (NRT) for smoking cessation in four European countries (Belgium, France, Sweden and the UK). METHODS: Markov simulations, using the Benefits of Smoking Cessation on Outcomes (BENESCO) model, were performed. We simulated the incidence of four smoking-related morbidities: lung cancer, chronic obstructive pulmonary disease, coronary heart disease and stroke. The model computes quality-adjusted life-years gained and incremental cost-effectiveness ratios. Incremental cost-utility ratios were calculated, adopting a lifetime perspective. Efficacy data were obtained from a randomized open-label trial: Week 52 continuous abstinence rates were 26.1% for varenicline and 20.3% for NRT. RESULTS: The analyses imply that for countries analysed, smoking cessation using varenicline versus NRT was associated with reduced smoking-related morbidity and mortality. The number of morbidities avoided, per 1000 smokers attempting to quit, ranged from 9.7 in Belgium to 6.5 in the UK. The number of quality-adjusted life-years gained, per 1000 smokers, was 23 (Belgium); 19.5 (France); 29.9 (Sweden); and 23.7 (UK). In all base-case simulations (except France), varenicline dominated (more effective and cost saving) NRT regarding costs per quality-adjusted life-year gained; for France the incremental cost-effectiveness ratio was 2803. CONCLUSION: This cost-effectiveness analysis demonstrated that since varenicline treatment was more effective, the result was increased healthcare cost savings in Belgium, Sweden and the UK. Our results suggest that funding varenicline as a smoking cessation aid is justifiable from a healthcare resource allocation perspective.}},
author = {{Bolin, Kristian and Wilson, Koo and Benhaddi, Hicham and Nigris, Enrico de and Marbaix, Sophie and Mork, Ann-Christin and Aubin, Henri-Jean}},
issn = {{1101-1262}},
keywords = {{nicotine replacement therapy; cost-effectiveness; smoking cessation; varenicline}},
language = {{eng}},
number = {{6}},
pages = {{650--654}},
publisher = {{Oxford University Press}},
series = {{European Journal of Public Health}},
title = {{Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries.}},
url = {{http://dx.doi.org/10.1093/eurpub/ckp075}},
doi = {{10.1093/eurpub/ckp075}},
volume = {{19}},
year = {{2009}},
}